- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.05. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings | ||
| PROFUSA Aktie jetzt für 0€ handeln | |||||
| 15.05. | Profusa moves to Nasdaq Capital Market amid compliance efforts | 1 | Investing.com | ||
| 15.05. | Profusa wechselt in den Nasdaq Capital Market, um Compliance-Anforderungen zu erfüllen | 5 | Investing.com Deutsch | ||
| 15.05. | Profusa, Inc.: Profusa Announces Listing Transfer to The Nasdaq Capital Market | 193 | GlobeNewswire (Europe) | BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling... ► Artikel lesen | |
| 08.05. | Profusa granted transfer to Nasdaq Capital Market, faces July compliance deadline | 1 | Seeking Alpha | ||
| 08.05. | Profusa, Inc.: Profusa Receives Favorable Nasdaq Listing Determination | 137 | GlobeNewswire (Europe) | BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the... ► Artikel lesen | |
| 08.05. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.05. | Profusa, Inc.: Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value | 202 | GlobeNewswire (Europe) | Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to... ► Artikel lesen | |
| 01.05. | Profusa, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 29.04. | Profusa passt Schuldenvereinbarung an und erhält Rüge von der NASDAQ | - | Investing.com Deutsch | ||
| 28.04. | Profusa, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 24.04. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.04. | Profusa, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 07.04. | What's Going On With Profusa Stock Tuesday? | 2 | Benzinga.com | ||
| 06.04. | Profusa Stock Soars On Deal Targeting Multi Billion Precision Diagnostics Space | 2 | Benzinga.com | ||
| 06.04. | Profusa plant Übernahme von Diagnostik-Plattform und kooperiert mit Mayo Clinic - Aktie steigt um 45 % | 3 | Investing.com Deutsch | ||
| 06.04. | Profusa to acquire multi-omics platform, partners with Mayo Clinic | 1 | Investing.com | ||
| 06.04. | Profusa, Inc.: Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform | 433 | GlobeNewswire (Europe) | Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications... ► Artikel lesen | |
| 06.04. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 6,026 | -1,57 % | Here's Why Investors Should Hold on to Teladoc Health Stock for Now | ||
| HIMS & HERS HEALTH | 22,720 | +0,09 % | Telemedizin-Aktie legt zu: 1,15-Milliarden-Deal: Hims & Hers expandiert radikal | © Foto: picture alliance / ZUMAPRESS.com | Avishek DasHims & Hers kauft sich mit Eucalyptus in neue Märkte ein - der Milliarden-Deal schürt Fantasie für den nächsten Wachstumsschub.Hims & Hers Health... ► Artikel lesen | |
| PLUS THERAPEUTICS | 4,850 | +6,01 % | PLUS THERAPEUTICS, INC. - 8-K, Current Report | ||
| HEALWELL AI | 0,540 | 0,00 % | HEALWELL verzeichnet im 1. Quartal 2026 eine Umsatzsteigerung von 316 % und verbessert die Kundenbindung | - HEALWELL erzielte im ersten Quartal 2026 einen Quartalsumsatz aus fortlaufender Betriebstätigkeit in Höhe von 33,2 Millionen $, was einem Anstieg um 316 % gegenüber dem im
ersten Quartal... ► Artikel lesen | |
| ORGANON | 11,590 | -0,04 % | Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia | SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines... ► Artikel lesen | |
| CO-DIAGNOSTICS | 5,725 | +1,69 % | Co-Diagnostics Reports First Quarter 2026 Financial Results | Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion
Executing Clinical Strategy with Upper Respiratory Submission Preparation... ► Artikel lesen | |
| VERU | 3,410 | +0,29 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 3,350 | +0,60 % | Jim Cramer on Clover Health: "You're in Pure Spec Mode There" | ||
| SENSEONICS | 5,850 | +0,86 % | Senseonics Holdings, Inc.: Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026 | ||
| ELEKTA | 5,150 | +2,39 % | Elekta AB: Year-end report May-April 2025/26 | Fourth quarterIn constant exchange rates, net sales decreased by 1 percent mainly driven by APAC, despite growth in China. Reported sales in SEK decreased by 8 percent amounting to SEK 4,762 M (5,156).Fourth... ► Artikel lesen | |
| IMUNON | 1,740 | 0,00 % | IMUNON announces $10M cash financing | ||
| PERSPECTIVE THERAPEUTICS | 2,696 | -10,13 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-a-NET in the Meningioma Cohort of a Phase 1/2a Study | SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 27,850 | +0,07 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| AXOGEN | 36,870 | 0,00 % | Axogen, Inc.: Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock | ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral... ► Artikel lesen | |
| NIAGEN BIOSCIENCE | 3,060 | +2,68 % | Niagen Bioscience, Inc: Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science | The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen and advancing understanding... ► Artikel lesen |
PROFUSA INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,003 (-1,23 %) liegt der Kurs bei 0,265 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROFUSA INC finden Sie auf Wallstreet Online.